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Abstract  
 
The lncRNA Myocardial Infarction Associated Transcript (MIAT) is involved in a number of diseases, 
including myocardial infarction and diabetic retinopathy. Emerging evidence suggests that MIAT expression 
levels are increased in different type of cancers, including breast cancer. In this study we further evaluated the 
role of MIAT in breast cancer and investigated the consequences of its silencing on breast cancer response to 
chemotherapeutic agents. Expression levels of MIAT mRNA in breast cancer were determined using 
TissueScan™ Breast Cancer cDNA Arrays. Breast cancer cell lines were transfected with MIAT specific 
siRNAs, with silencing confirmed using RT-qPCR and the effects on breast cancer cell survival and response to 
different apoptotic stimuli determined. MIAT transcript levels were significantly elevated in breast cancer 
samples. Such increase was specific to the early stages of the disease, ER, PR +ve, HER –ve and TNBC 
samples. Silencing of MIAT induced growth arrest and increased basal apoptosis. Reduced levels of MIAT 
augmented the apoptotic response of breast cancer cells to a wide range of apoptotic stimuli. Our results also 
showed that MIAT down-regulation was associated with a decrease in OCT4 mRNA, suggesting the existence 
of a MIAT/OCT4 regulatory loop, similar to that observed in malignant mature B cells. Taken together with the 
recent demonstration of oncogene characteristics, our observations suggest that MIAT plays an important role in 
breast tumorigenesis. Strategies to decrease MIAT expression levels may improve sensitivity to therapy in 
breast cancer by enhancing the apoptotic responses to conventional chemotherapies. 
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Introduction  
The term long non-coding RNA (lncRNA) is regularly used to describe the class of RNA transcripts longer than 
200 nucleotides which do not encode a protein [1-2]. LncRNAs have received attention due to their tissue- and 
developmental-specific expression patterns and their functional importance in many physiological and 
pathological processes [3]. Similar to mRNAs, lncRNAs are RNA polymerase II transcripts, processed via 
capping at the 5’ end, polyadenylated at the 3’ end and spliced. Their strong cell-type specific and temporal 
expression has confirmed their importance and several of these lncRNAs have now been characterised to play 
key roles in the control of multiple biological processes, such as gene expression, epigenetic regulation and 
chromatin remodelling [3,4].  
 
Classes of lncRNAs include long intergenic ncRNAs, natural antisense transcripts to protein coding genes, 
pseudogene-derived transcripts, and intronic lncRNAs [5-6]. These transcripts are known to regulate gene 
expression, guide chromatin-modifying complexes to specific loci, and RNA splicing by acting as signals, 
scaffolds, guides, or decoys [7].  Another group of lncRNAs include those that accumulate predominantly in the 
nucleus and serve as important components of specific nuclear bodies [8]. Some of these lncRNAs are emerging 
as important players in the pathogenesis of many cancers, since their expression is deregulated in tumor tissues 
[8]. GOMAFU/MIAT (Myocardial Infarction Associated Transcript) is of particular interest in breast cancer 
since its expression is upregulated in high-grade tumors compared to low-grade ones [9]. 
 
MIAT was previously known as RNCR2 (retinal non-coding RNA2) and GOMAFU. Increasing evidence 
confirms the role of MIAT lncRNA in a number of cellular processes, such as the formation of nuclear bodies 
and neurogenic commitment [10]. In addition, MIAT lncRNA is involved in a number of diseases, including 
myocardial infarction [11-12], diabetic retinopathy [13], microvascular dysfunction [14], and paranoid 
schizophrenia [15]. Recent studies have also implicated MIAT in cancer initiation and progression [16].  MIAT 
was found to be upregulated in neuroendocrine prostate cancer (NEPC) and its up-regulation was associated 
with Polycomb genes, which play a key role in NEPC initiation and progression [16]. Moreover, MIAT was 
found to be up-regulated in aggressive forms of chronic lymphocytic leukemia (CLL) and was suggested as a 
new biomarker for detecting the advance stages of CLL [16]. In breast cancer cells, MIAT knockdown inhibits 
cell proliferation and stimulates apoptosis [9]. Indeed, reduced levels of MIAT expression decreased migration 
and invasion in breast cancer cells and inhibited human breast tumor growth in a xenograft mouse model, 
suggesting that MIAT acts as an oncogene [17]. The effects of MIAT down-regulation on promoting apoptosis 
could have implications for breast cancer therapy, since the mode of action of many chemotherapeutic drugs is 
largely dependent on their interaction with apoptotic signalling pathways. While the effects of down-regulation 
of MIAT expression levels on breast cancer cell survival have been examined, the consequences of reduced 
MIAT levels for chemotherapeutic drug action in breast cancer cells have not been examined to-date.   
 
In this study, we have focussed on the implications of reduced MIAT expression on the response to different cell 
death stimuli in breast cancer cells. First, we have evaluated the expression of MIAT in samples from different 
stages of breast cancer. Second, we have examined the effects of MIAT down-regulation on the short and long 
term survival of breast cancer cells and on the expression of OCT4, since OCT4 together with MIAT constitutes 
a regulatory loop in embryonic stem cells [18, 19] and malignant B cells [16]. Finally, we have investigated the 
hypothesis that reduction of MIAT expression levels enhances the response of breast cancer cells to cell death-
inducing stimuli, including chemotherapeutic drugs and ultraviolet-C (UV-C).  
 
 
Materials and Methods  
 
Materials  
 
MCF7, MDA-MB-231 and Hs58T cell lines were from ATCC-LGC Promochem (Teddington, UK). All cell 
culture materials and classical chemotherapeutic drugs were from Sigma-Aldrich Ltd (Gillingham, UK). 
TissueScan qPCR Breast Cancer Disease Panels I, II, and IV (BCRT101, BCRT102, BCRT104) were purchased 
from OriGene Technologies. MIAT specific siRNAs were from Qiagen (Crawley, UK). Negative control 
siRNA, TRIzol, reverse transcription reagents and TaqMan assays were from Life Technologies Ltd (Paisley, 
UK). SensiFast Probe Hi-ROX kit was obtained from Bioline (London, UK). RQ1 RNase-free DNase was from 
Promega (Southampton, UK). Nucleofector solution V was from Lonza Biosciences (Verviers, Belgium).  
 
Methods  
 
Cell culture  
The breast cancer cell lines MCF7, MDA-MB- 231 and Hs58T derived from secondary stocks of cells which 
had been frozen down within two weeks of receipt from the ATCC. Cells were cultured at 37
0
C in a humidified 
incubator in the presence of 5 % CO2 in RPMI-1640 supplemented with 2 mM L-glutamine, 1 mM sodium 
pyruvate, 10 mM HEPES, 10 % fetal bovine serum and 50 g/mL gentamicin. Cells were replaced with fresh 
stocks after a maximum culture period of two months. 
 
RNA interference by siRNA 
Cells were nucleofected with Qiagen siRNAs using programmes E-014 for MCF7 and X-013 for MDA-MB-231 
and Hs58T, as described previously [20]. Three different MIAT siRNAs targetting different locations on exon 5 
were used termed M1 (Product code # SI04314919; target site 6488-6508), M2 (# SI04287423; target site 7222-
7242) and M3 (# SI00582799; target site 9735-9755). Control cells received a negative control siRNA (NC; 
code AM4611). Following nucleofection, cells were plated in 3 mL complete RPMI-1640 medium in 6-well 
plates.  
 
Induction of cell death  
At 72 hours post-siRNA nucleofection, cells were trypsinized, sampled for RNA extraction, counted using a 
haemocytometer following staining with Trypan blue (0.4 % w/v; Sigma) and then seeded (0.8 x 10
5
 cells/mL) 
into 12-well plates. In some experiments, ultraviolet-C (UV-C) irradiation (dose: 20 J/m
2
) was performed prior 
to plating, while controls were mock-irradiated [21]. For drug treatments, cells were cultured for 20 hours, 
before addition of 5-fluorouracil (5-FU; 175M), docetaxel (10µM), Nutlin-3 (5µM), mitoxantrone (50µM) or 
vehicle (0.25% v/v dimethyl sulphoxide). Cells were cultured for 48 hours before assessment of cell viability 
and apoptosis 
 Cell survival assays and cell cycle analysis  
Apoptosis level was determined by flow cytometry using a Muse annexin V and dead cell assay kit, according to 
the manufacturer’s protocol (Merck Millipore, Darmstadt, Germany) [20]. Apoptosis was also measured by 
determining caspase activity using CaspaTag Pan-Caspase In Situ Assay Kit, according to the supplied 
instructions (Millipore, Watford, UK).   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
Cell viability was determined using a commercial Cell Count and Viability Kit and a Muse flow cytometer 
(Merck Millipore, Darmstadt, Germany) [20].  Clonogenic assays were performed to assess long term survival. 
Transfected cells were re-plated in culture medium supplemented with 10 % (v/v) cell-conditioned medium in 6-
well plates and cultured for 3 weeks. The number of the colonies was determined after staining with crystal 
violet stain (0.5% (w/v) in methanol) for 10 minutes.   
 
Cell cycle analysis was carried using nuclear propidium iodide (PI)-staining procedure and flow cytometry [20]. 
Transfected cells were harvested 48 hours post-transfection and re-plated in fresh medium at 2 ×10
5
 cells/well in 
6-well plates. Following incubation for24 hours, 1 million cells were washed in PBS before re-suspending the 
pellet in 200 μL PBS. Cells were then fixed in 1 mL ice cold (70% ethanol / 30% PBS) and stored at –20°C for 
at least 3 hours prior to cell cycle analysis. Fixed cells were centrifuged for 5 minutes at 1500 rpm. The 
supernatant was discarded and the cell pellet was re-suspended in 200 μL of Muse Cell Cycle Reagent (Merck 
Millipore # MCH100106). Cells were incubated for 30 minutes in the dark and data acquisition was carried out 
using the Millipore Muse cell analyser [20].   
 
Real time RT-PCR (RT-qPCR)  
Total RNA from 10
7
 cells was isolated using Trizol according to the manufacturer’s instructions. 5 µg of RNA 
was reverse transcribed using SuperscriptTM II RNase H reverse transcriptase and random primers as described 
previously [21]. TaqMan gene expression assays (assay codes Hs99999901_m1 for 18S and Hs00402814_m1 
for MIAT) were employed. Assays contained 10 ng sample cDNA or 0.2–30 ng standard cDNA (prepared from 
cDNA from MCF7, MDA-MB-231 and Hs58T breast cancer cells). The ABI Prism 7000 sequence detection 
system was used to measure real-time fluorescence. Input amounts of samples were calculated from their 
respective threshold cycle (CT) values, using standard curves generated with each assay. Data were expressed 
relative to 18S rRNA. 
 
Human tissue samples 
Real time PCR was also performed on TissueScan™ Cancer and Normal Tissue cDNA Arrays using Breast 
Cancer cDNA Array I, II, and IV covering cDNA from 16-normal, 23-Stage I, 58-II, 42-III and 5-IV samples, 
whose clinical and pathological features are freely available at the following address: 
http://www.origene.com/qPCR/Tissue-qPCR-Arrays.aspx. Standard curve of threshold cycle (CT) value versus 
log input standard cDNA was constructed by linear regression, and the equation of the line was used to calculate 
input amounts of samples from their respective CT values. Data were expressed relative to 18S.  
 
Statistical analysis  
Data are presented as mean ± standard error of the mean (S.E.). Data were analyzed by one-way analysis of 
variance, using Bonferroni's multiple comparison test (MCT).  Data from the Breast Cancer cDNA Arrays were 
analysed by Mann–Whitney rank sum test between normal and cancer samples. Comparison between normal 
specimen and different stages or subtypes of cancer were carried out using Kruskal–Wallis one-way analysis of 
variance (ANOVA) on ranks, followed by Dunn’s test for comparisons against the control group. GraphPad 
Prism v4.03 was used to construct the graphs and perform Statistical analyses.  
 
Results 
 
Expression of MIAT lncRNA in breast cancer 
Previous studies have reported an increased in MIAT expression levels in high-grade breast tumors compared to 
low-grade ones [9]. MIAT expression was also found to be upregulated in ER, PR and Her2 positive tumor 
tissues [9]. To further investigate whether the mRNA expression levels of MIAT exhibit changes in breast 
cancer, we utilised breast cancer cDNA arrays (BCRT101, BCRT102 and BCRT104) from OriGene Inc and 
determined MIAT expression levels in breast cancer and normal tissues. Real time PCR was performed using 
TaqMan gene expression assays targetting MIAT and 18S, which was used as an endogenous control gene. The 
results revealed that the overall mean of MIAT expression level was significantly higher in breast tumor 
compared with the mean of MIAT expression levels in normal breast tissue (Fig. 1A). However, scattergram 
analysis of these data demonstrated heterogeneity (Fig.1.B) and further analysis revealed an increased in MIAT 
expression level in stage I-II breast samples but not in stage II-IV (Fig.1C). Stratification of patients into groups 
according to molecular subtypes showed that compared to the normal breast samples MIAT expression was not 
changed in the triple positive (ER, PR and HER2 positive) samples, but was significantly increased in ER, PR 
+ve, HER –ve breast cancer subtypes and in triple negative breast cancer (TNBC) (Fig. 1D). The increase in 
MIAT levels was more enhanced (2-fold) in TNBC samples.  
 Fig. 1. MIAT expression levels in breast cancer. The level of MIAT lncRNA was determined in 128 tumor 
samples and compared to 16 normal breast tissue samples. A) MIAT expression showed significant increase in 
the full data sets of breast tumors compared to normal. B) Corresponding scattergrams of these data are shown. 
C) Analysis of the data revealed that there is a highly significant upregulation of MIAT lncRNA in stage I-II 
disease. D) Stratification of MIAT expression levels according to the molecular subtypes showed variation in 
MIAT expression. MIAT expression was not changed in the triple positive (ER, PR and HER2 positive) 
samples, significantly increased in ER, PR +ve, HER –ve and TNBC breast cancer subtypes (Mann-Whitney 
Rank Sum Test (A and B) and Kruskal–Wallis one-way ANOVA on ranks (C and D); **P<0.01 and ***P< 
0.001; n = 16-normal, 128-breast adenocarcinoma specimens). 
 
Effect of MIAT silencing on OCT4 mRNA expression and on the survival of breast cancer cells 
To examine the effects of reduced MIAT expression on breast cancer cell survival, MIAT siRNAs were 
employed to silence endogenous MIAT expression in two cell lines, MCF7 and MDA-MB-23. Three different 
siRNAs were employed to reduce the possibility of ‘off-target’ effects. The influence of MIAT silencing on the 
short and long term survival of breast cancer cells was examined under basal conditions.   
In MCF7 cells, all three siRNAs reduced MIAT transcript levels by up to 70-85% compared to control levels 
(Fig. 2A). OCT4 is a transcription factor reported to promote MIAT expression and a positive correlation 
between MIAT and OCT4 mRNA expression levels have been reported [16]. Therefore, the effects of reduced 
MIAT expression levels on the expression of OCT4 mRNA were also determined. Down-regulation of MIAT 
was found to be associated with a decrease in OCT4 mRNA levels, with OCT4 transcript levels found to be 65-
80% lower than that of control cells (Fig. 2B), indicating the positive relationship between MIAT and OCT4 
mRNA expression. MIAT down-regulation caused a significant increase in basal apoptosis levels and a 
reduction in both short term survival and the clonogenic activity (Fig. 2C, 2D and 2E).   Analysing the cell cycle 
profile revealed that that MIAT silencing causes an increase in the percentage of cells in G0/G1, and a 
concomitant significant decrease in the percentage of cells in S and G2/M phase (Fig. 2F).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.  Effect of MIAT silencing on the survival of MCF7 cells. MCF7 cells (n=4 cultures) were transfected 
with the indicated MIAT siRNA or negative control (NC) siRNA and harvested at 72 h post transfection. Cells 
were re-plated for assessment of cell survival after a further 48h. A) At 72 h post-transfection, RT-qPCR 
analysis confirmed decreased cellular MIAT levels in cells treated with MIAT siRNAs. B) Cells transfected 
with MIAT siRNAs expressed less OCT4 mRNA as confirmed with RT-qPCR. C) Silencing of MIAT enhanced 
basal apoptosis. D) Short term viability was reduced 48 h post re-plating. E)  Colony formation in long-term 
clonogenic assays was significantly decreased. F) Cell cycle analysis revealed that MIAT silencing caused an 
elevation in the percentage of cells in G0/G1 phase.  *P<0.05, **P<0.01 and ***P<0.001  versus cells 
transfected with NC siRNA (one-way ANOVA and Bonferrroni’s MCT). 
 
 
Consistent with these observations, MIAT down-regulation (80% decrease compared to control) in TNBC 
MDA-MB-231 cells (Fig. 3A) was associated with a 65-80% decrease in OCT4 levels (Fig. 3B) and a reduction 
in short term survival and clonogenic activity (Fig. 3D, 3E). Basal apoptosis levels were also enhanced by 
MIAT silencing (Fig. 3C). Cell cycle analysis showed that similar to observations in MCF7 cells, silencing of 
MIAT in MDA-MB-231 increased the percentage of cells in G0/G1, with an associated decrease in the 
percentage of cells in S and G2/M phase (Fig. 3F).  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The effect of MIAT silencing on UV-C and chemotherapeutic drugs- induced cell death in breast cancer 
cells 
 
Fig. 3. Effect of MIAT siRNAs on the survival of MDA-MB-231 cells. MDA-MB-231 cells were transfected 
with the indicated MIAT siRNA or negative control (NC) siRNA and harvested at 72 h post transfection (n=4 
cultures). A) At 72 h post-transfection, RT-qPCR analysis confirmed decreased cellular MIAT levels. B) mRNA 
levels of OCT4 were also reduced in MIAT transfected cells. C) Apoptosis levels measured 48 h post re-plating 
showed that silencing of MIAT enhanced basal apoptosis. D) Transfection of MIAT siRNAs caused a reduction 
in short term viability. E) Clonogenic ability was reduced in the cells transfected with MIAT siRNAs. F) Cell 
cycle analysis revealed that MIAT silencing caused an elevation in the percentage of cells in G0/G1 phase. 
*P<0.05, **P<0.01 versus and ***P< 0.001  cells transfected with NC siRNA (one-way ANOVA and Dunnett’s 
MCT). 
 
 
When MCF7 cells were irradiated with UV-C light, MIAT knockdown enhanced apoptosis levels (Fig. 4A) and 
the consequent decrease in short (Fig. 4B) and long term (Fig. 4C) culture viability. Consistent with these 
observations, MIAT knockdown in MDA-MB-231 cells stimulated apoptosis induction by UV-C irradiation 
(Fig. 4D), as well as the associated losses in culture viability (Fig. 4E) and clonogenic activity (Fig. 4F). It is 
worth noting that the extent of MIAT knockdown -mediated stimulation of apoptosis in response to UV-C 
irradiation tended to be similar to that seen in the absence of any apoptotic stimuli, suggesting that there is an 
additive rather than synergistic effect of MIAT silencing on UV-induced cell death. Further experiments 
involving the assessment of caspase activity confirmed that MIAT knockdown in both cell lines MCF7 and 
MDA-MB-231 is specifically associated with higher levels of apoptosis in both basal conditions and after UV-C 
treatment (Fig. 5A and 5B).  Similar results were obtained upon treatment with the chemotherapeutic drugs, 
docetaxel, 5-fluoracil, mitoxantrone, nutlin 3a, where MIAT silencing in MCF7 (Fig. 6A-H) and MDA-MB-231 
(Fig.7 A-H) enhanced the apoptotic response and the loss of culture survival of these cells. Again the effects of 
MIAT silencing were additive to the effects of apoptotic stimuli on the negative cells. 
  
 
Fig. 4.  Effect of MIAT siRNA on UV-C induced cell death in MCF7 and MDA-MB-231 cells. Breast cancer 
cells (n=4 cultures) were transfected with the indicated MIAT siRNA or negative control (NC) siRNA and 
harvested at 72 h post transfection. Cells were exposed to UV-C irradiation and cell survival parameters were 
determined 48h post treatment. For all figure parts, MCF7 results are displayed in the left-hand panel and MDA-
MB-231 cells in the right-hand panel. A) and D)  Reduced levels of MIAT enhanced UV-C- induced apoptosis. 
B) and E) MIAT silencing increased UV-C-induced loss of cell survival. C) and F) MIAT silencing also 
promoted UV-induced loss of clonogenic activity.  *P<0.05 and  **P<0.01 versus cells transfected with NC 
siRNA (one-way ANOVA and Dunnett’s MCT). 
 Fig. 5.  MIAT silencing promotes caspase activation in breast cancer cells. Breast cancer cells were transfected 
with the indicated MIAT siRNA or negative control (NC) siRNA. At 72 h post transfection, cells were 
trypsinized and treated  ± UV-C light (20 J/m
2
). Cells were incubated for 24h before the assessment of caspase 
activity.  Percentage of cells containing activated caspases was determined using fluorescence microscopy. A) 
MIAT silencing caused an enhanced caspase activity in MCF7 breast cancer cells. B) Transfection of MIAT 
siRNAs caused an enhanced caspase activity in MDA-MB-231 breast cancer cells. *P < 0.05 & 
**P < 0.01 versus cells transfected with NC (one-way ANOVA and Bonferrroni's MCT; n = 4). 
  
Fig. 6.  Effect of MIAT siRNAs on the survival of MCF7 cells after treatment with chemotherapeutic drugs.  
MCF7 cells (n=4 cultures) were transfected with MIAT siRNA or negative control (NC) siRNA and after 72 h, 
treated with either 5-FU ( 175 M), docetaxel (10 M), nutlin-3 (5 M), mitoxantrone (50 μM) or vehicle (0.25 
% dimethyl sulphoxide). Following 48h incubation, cell viability was determined by flow cytometry on 
harvested cells and apoptosis was determined by annexin V staining and flow cytometry. For all figure parts, 
cell viability is displayed in the left-hand panel and apoptosis in the right-hand panel. A) and B) MIAT silencing 
enhanced the loss of viability and apoptosis induced by  docetaxel. C) and D)  Similar effects were observed 
with 5-FU. E) and F) Cells transfected with MIAT siRNAs exhibit enhanced loss of cell viability and an 
increased in apoptosis level after mitoxantrone treatment.  G) and H) Loss of viability and induction of 
apoptosis by nutlin-3a were enhanced in MIAT siRNA transfected cultures.  *P<0.05, **P<0.01 and  ***P< 
0.001  versus cells transfected with NC siRNA (one-way ANOVA and Bonferrroni’s MCT).  
 
 Fig. 7. Effect of MIAT silencing on chemotherapeutic drug-induced death of MDA-MB-231 TNBC cell line. 
MDA-MB-231 cells (n=4 cultures) were transfected with the indicative MIAT siRNA or negative control (NC) 
siRNA. At 72 h post transfection, cells were re-plated and treated with either 5-FU (175 M), docetaxel (10 
M), nutlin-3 (5 M), mitoxantrone (50 μM) or vehicle (0.25 % dimethyl sulphoxide). After 48h incubation, 
cell viability was determined by flow cytometry and apoptosis was determined by annexin V staining and flow 
cytometry.  For all figure parts, cell viability is displayed in the left-hand panel and apoptosis in the right-hand 
panel. A) and B) MIAT silencing enhanced the loss of viability and apoptosis caused by docetaxel. B) and C) 
Cells transfected with MIAT siRNAs exhibit enhanced loss of cell viability and an increased in apoptosis level 
after 5-FU treatment. E) and F)  MIAT transfected cells showed decreased cell viability and enhanced apoptosis 
after mitoxantrone treatment. G) and H) Same results were obtained with nutlin. *P<0.05 and  **P<0.01 and  
***P< 0.001  versus cells transfected with NC siRNA (one-way ANOVA and Bonferrroni’s MCT). 
 
MIAT silencing also induces apoptosis in triple-negative Hs58T cells 
To further confirm our observations that silencing MIAT is associated with an increase in apoptosis levels in 
breast cancer cells, we examine the influence of MIAT silencing on the cell survival of another TNBC cell line 
Hs58T. Hs58T cells were transfected with the three MIAT specific siRNAs and cell survival was examined 
under basal conditions and after apoptosis induction by UV-C irradiation.  Decreased MIAT levels (Fig. 8A) 
under basal conditions were associated with an increase in basal apoptosis (Fig. 8B) and a decrease in both 
short-term viability (Fig. 8D) and long-term survival (Fig. 8F). MIAT knockdown also enhanced apoptosis 
induction by UV-C irradiation (Fig. 8C) as well the associated loss of short-and long- term cell survival (Fig. 8E 
and 8G). Thus, as for MCF7 and MDA-MB-231, MIAT silencing leads to an increase in apoptosis and reduction 
in Hs58T cell survival.   
 
 
  
 
Fig. 8. Effect of MIAT knockdown on the basal survival and UV-C induced cell death in triple-negative Hs58T 
breast cancer cells. Hs58T cells (n = 4 cultures) were transfected with the indicated MIAT siRNA or negative 
control (NC) siRNA. Cells were harvested at 72 h post transfection and were treated ± UV-C irradiation and re-
plated for a further 48 h before the assessment of cell survival. A) RT-qPCR analysis confirmed decreased 
cellular MIAT levels at 72 h post-transfection in cells treated with MIAT siRNAs. B) Basal apoptosis levels 
were increased in MIAT siRNA transfected cells. C) Transfection with MIAT siRNAs enhanced UV-C -induced 
apoptosis. D) Correspondingly cell viability was also reduced in cells transfected with MIAT siRNAs. E) Loss 
of viability caused by UV was more enhanced in the cells transfected with MIAT siRNAs. F) MIAT silencing 
induces loss of clonogenic activity. G)  UV-C-induced loss of colony forming ability was more enhanced in 
MIAT siRNA transfected cells.  *P<0.05, **P< 0.01 and ***P<0.001 versus cells transfected with NC siRNA 
(one-way ANOVA and Bonferrroni’s MCT).  
 
Discussion  
MIAT was originally identified in the neurons of the mouse retina and was later found to be highly expressed in 
the nervous system throughout development [22]. Its role was subsequently confirmed in a number of cellular 
processes, including the formation of nuclear bodies [23], regulation of mammalian retinal cell differentiation 
[24], and neurogenic commitment [25].  In addition, MIAT was shown to be involved in a number of diseases, 
such as myocardial infarction [10,11],  diabetic retinopathy [12], microvascular dysfunction [13] and paranoid 
schizophrenia [14]. Evidence implicating MIAT in cancer is now emerging and MIAT is selectively up-
regulated in neuroendocrine prostate cancer [15] and in primary leukemic cells from patients with aggressive 
forms of CLL [16].  
 
A role of MIAT lncRNA in breast cancer is also emerging; studies have reported an increased MIAT expression 
levels in advanced breast tumors, where its overexpression was shown to be associated with lymph node 
metastasis [17]. Using gene expression profiling of breast cancer tissues, the present study confirms that MIAT 
expression level is significantly increased in breast cancer, specifically in the early stages of the disease (stage I 
and II), suggesting that MIAT over-expression is important in the early stages of breast oncogenesis and may 
play a key role throughout the development of malignancy. On the other hand, there was no significant increase 
in MIAT levels in breast cancer samples in the late stages of the disease, this could be due to the small sample 
size. Unlike previous studies that showed an increased MIAT expression levels in the triple positive (ER, PR, 
Her2 positive) tumor tissues [9], our results showed that MIAT expression was not changed in the triple positive 
breast cancer samples. However, MIAT expression levels showed significant increase in ER, PR +ve, HER –ve 
and the triple negative breast cancer (TNBC) breast cancer subtypes. The increased in MIAT expression levels 
was more enhanced in the TNBC samples, consistent with the observations that MDA-MB-231 TNBC cell line 
showed the highest expression levels of MIAT when compared to other breast cancer cell lines [17].  Together, 
the data suggest that increased MIAT expression levels might be associated with an increase in the metastatic 
ability of breast cancer.  
 
Functional studies have previously reported that MIAT regulates cancer cell survival, with decreased MIAT 
expression levels inhibiting cell proliferation in breast cancer cells [9, 17], and malignant B cells [16]. Our 
results further support such observations and confirms that MIAT down-regulation is associated with enhanced 
basal apoptosis levels and a decrease in short and long term survival of different types of breast cancer cells. 
Our study further extends these findings and shows, for the first time, that MIAT not only regulates basal 
apoptosis levels, but it also modulates the response of breast cancer cells to a range of apoptotic stimuli.  Low 
levels of MIAT were consistently associated with increased cell death in response to both physical and chemical 
stimuli. MIAT silencing enhanced breast cancer cell response to a diverse range of apoptotic stimuli acting via 
different mechanisms, including DNA damage (UV-C irradiation), inhibition of mouse double minutes clone 2 
(MDM2) (nutlin-3a), microtubule stabilizing (docetaxel), inhibition of topoisomerase II  (mitoxantrone), and 
inhibition of thymidylate synthase (5-fluorouracil),  indicating that MIAT participates in a late common step that 
can connect the different apoptotic pathways activated by these agents.  Such observation is characteristic of the 
actions of key apoptosis regulators such Inhibitor of Apoptosis Protein (IAP) family and pro- and anti-apoptotic 
members of the Bcl-2 family, for which their differential expression is key in determining cancer cell sensitivity 
to cell death induced by different stimuli [26,27]. It is therefore important to examine the functional 
relationships associating MIAT with these key regulators of apoptosis execution.  Indeed, reduced levels of 
MIAT in PC9 lung cancer cells were recently found to be associated with a decrease in Bcl-2 and an increase in 
Bax expression levels [28], providing further evidence that associates reduced MIAT levels with an enhanced 
responses to a diverse range of cell death stimuli and raising the possibility that increased MIAT levels might 
contribute to the development of drug resistance in metastatic disease.  
 
OCT4 is a transcription factor that contributes with MIAT in forming a regulatory feedback loop that regulates 
cell fate [16,18,29,30]. Gomafu, the mouse homologue of MIAT, has been shown to bind to OCT4 gene leading 
to an increase in its expression and OCT4 was also reported to positively regulate Gomafu transcription in 
mouse ES cells [18]. The existence of such a regulatory feedback loop was further validated in aggressive 
chronic lymphocytic leukaemia, where MIAT and OCT4 were found to increase survival and proliferation and 
suppress apoptotic cell death in malignant mature B cells and in cancer stem cell-like cells [16].  OCT4 
overexpression increases cell proliferation and inhibits apoptosis induction in myeloid cells with mature B cell 
phenotype and in cancer stem cell-like cells, whereas its down-regulation increases cell death and inhibits 
proliferation [16, 31].  The present work also supports the existence of a MIAT and OCT4 axis involved in the 
regulation of breast cancer cell survival. 
 
Consistent with others [9], our studies showed that MIAT silencing altered the cell cycle profile causing an 
increase in the percentage of cells in G1 phase and a concomitant decrease in the cells in G2/M phase.  These 
effects might be due to the decreased levels of OCT4 in these cells.  Suppression of OCT4 expression leads to 
the activation of the cyclin-dependent kinase inhibitor p21 [31]. Active p21 acts as tumor suppressor by 
promoting cell cycle arrest in G1 and therefore inhibiting cell cycle progression [31].  Besides its role as co-
activator for OCT4 mRNA expression, MIAT acts as a competing endogenous RNA (ceRNA), where it forms a 
regulatory feedback loop with miRNA-150-5p and VEGF (vascular endothelial factor) [18,33,34].  MIAT also 
acts as a ceRNA in human lens epithelial cells (HLEC) where it forms a feedback loop with Akt and miR-150-
5p to regulate HLEC function and survival [35].  
 
In a wide variety of physiological settings, the balance between apoptosis and cell proliferation is important in 
tissue development, regulation of cell number and removal of unwanted and harmful cells. Consequently, 
dysfunctional apoptosis and uncontrolled cell proliferation can result in a wide variety of diseases, including 
cancer [35–37]. Defective apoptosis is also associated with resistance to conventional chemotherapies since the 
actions of many anti-cancer chemotherapeutic agents depend on their interactions with apoptotic signalling 
pathways [25, 26, 36-41]. The present study shows that MIAT lncRNA is upregulated in breast cancer and in 
particular in TNBC, suggesting that MIAT may act as oncogene. The findings that reduced levels of MIAT 
enhanced both basal apoptosis of breast cancer cells and their response to a range of apoptotic stimuli could 
therefore have important clinical significance in relation to the response of breast tumors to cytotoxic therapy. 
Given the observations that comparable effects of MIAT silencing were witnessed in triple positive and triple 
negative breast cancer cells, whilst the expression levels of MIAT varied in relation to tumour grading by 
clinical stages, further studies using the MCF10 series representing different cancer stages should shed further 
light on the role of MIAT in breast cancer progression. 
 
Conclusion 
Our findings indicate that MIAT expression level is increased in breast cancer. MIAT was found to be a key 
regulator of breast cancer cell survival.  Reduced levels of MIAT inhibited short and long term survival, 
increased basal apoptosis and enhanced breast cancer cell apoptotic response to a range of apoptotic stimuli in 
an additive way. Our results suggest that approaches to decrease MIAT levels in breast tumors, coupled to 
conventional chemotherapeutic strategies, may prove beneficial in improving breast cancer patient outcomes. 
Such an approach may be particularly beneficial for TNBC which often exhibits resistance to conventional 
chemotherapies. Our current findings in breast cancer cell lines and recent findings in lung cancer [27] may be 
relevant to other cancers characterised by increased MIAT levels, including ovarian cancer [42] and gastric 
cancer [43]. Future studies will determine the potential use of MIAT as biomarker and specific therapeutic 
target. 
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